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Abstract
Background: We evaluated the performance of the Becton Dickinson Veritor™ System Flu A + B rapid influenza
diagnostic test (RIDT) to detect influenza viruses in respiratory specimens from patients enrolled at five surveillance
sites in Kenya, a tropical country where influenza seasonality is variable.
Methods: Nasal swab (NS) and nasopharyngeal (NP)/oropharyngeal (OP) swabs were collected from patients with
influenza like illness and/or severe acute respiratory infection. The sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) of the RIDT using NS specimens were evaluated against nasal swabs
tested by real time reverse transcription polymerase chain reaction (rRT-PCR). The performance parameter results
were expressed as 95% confidence intervals (CI) calculated using binomial exact methods, with P < 0.05 considered
significant. Two-sample Z tests were used to test for differences in sample proportions. Analysis was performed
using SAS software version 9.3.
Results: From July 2013 to July 2014, 3,569 patients were recruited, of which 78.7% were aged <5 years. Overall, 14.
4% of NS specimens were influenza-positive by RIDT. RIDT overall sensitivity was 77.1% (95% CI 72.8–81.0%) and
specificity was 94.9% (95% CI 94.0–95.7%) compared to rRT-PCR using NS specimens. RIDT sensitivity for influenza A
virus compared to rRT-PCR using NS specimens was 71.8% (95% CI 66.7–76.4%) and was significantly higher than
for influenza B which was 43.8% (95% CI 33.8–54.2%). PPV ranged from 30%–80% depending on background
prevalence of influenza.
Conclusion: Although the variable seasonality of influenza in tropical Africa presents unique challenges, RIDTs may
have a role in making influenza surveillance sustainable in more remote areas of Africa, where laboratory capacity is
limited.
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Background
In many tropical countries, the capacity for influenza
virus diagnostic testing in clinical settings is limited. Al-
though many point-of-care rapid influenza diagnostic
tests (RIDTs) have been evaluated in temperate settings
[1, 2], little information is available on the performance
of RIDTs in tropical areas. Compared to temperate
developed countries [3], the seasonality of influenza vi-
ruses is less predictable in sub-Saharan Africa (SSA).
The populations of SSA also tend to be younger [4, 5],
with more variable healthcare access and utilization [6],
and have a greater prevalence of some chronic co-
infections [7, 8]. Influenza has a clear marked seasonality
in temperate regions [9–11]. This is less the case in the
tropics where influenza circulation may occur through-
out the year. RIDTs have been shown to perform well
during the high influenza activity [12, 13]. However
there are fewer data pertaining to their performance in
clinical settings in tropical Africa where it is possible
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that RIDTs could facilitate greater awareness of influ-
enza; improve the practical relevance of influenza sur-
veillance in locations where laboratory confirmation may
take days to weeks; and possibly inform clinical manage-
ment and infection prevention and control practices at
the clinic or hospital level [14]. The Becton Dickinson
(BD) Veritor™ System (Becton, Dickinson and Company,
Franklin Lakes, New Jersey) RIDT is intended for use in
clinical settings. We implemented this test to detect sea-
sonal influenza virus infections in both outpatient and
inpatients reporting to existing respiratory disease sur-
veillance systems in Kenya. We compared the perform-
ance of the BD Veritor test to detect influenza A and B
infections, against the performance of real time reverse
transcription polymerase chain reaction (rRT-PCR) that
is used in the surveillance system.
Methods
Setting
The study was implemented at five inpatient and out-
patient influenza surveillance sites in Kenya. The five
sites were selected to represent different geographical re-
gions in Kenya (Fig. 1) and included: 1) Coast County
referral hospital, located in the city of Mombasa; 2) Na-
kuru County referral Hospital, located in the Rift Valley;
3) Nyeri County referral Hospital, located in central
Kenya; 4) St. Elizabeth Lwak Mission Hospital, a non-
profit health facility in rural western Kenya that partici-
pates in the Population Based Infectious Disease Surveil-
lance (PBIDS) system run by the Kenya Medical
Research Institute (KEMRI) and the Centers for Disease
Control (CDC) in Kenya, and; 5) Tabitha Medical Clinic,
located in Kibera, an informal urban settlement in
Nairobi [15, 16], that is also part of PBIDS. While
Tabitha Medical Clinic is exclusively an outpatient clinic,
all other facilities included inpatient and outpatient sur-
veillance components.
Study period
Influenza virus circulation in Kenya occurs year-round
with primary peaks often occurring during the months
of July–November, and secondary peaks during the
period of March–May [4, 17]. For this study we re-
cruited patients during a 13-month period from July 1,
2013 to July 31, 2014.
Surveillance design and case definitions
Outpatient surveillance was conducted at each of the
five sites for the first five daily cases of influenza like ill-
ness (ILI) identified among those aged ≥2 months. ILI
was defined as axilla temperature ≥38 °C and either
cough or sore throat with onset within the last seven
days. Surveillance for severe acute respiratory illness
(SARI) was undertaken at all five sites and captured all
SARI cases identified throughout the day, although with
some modification to the case definition applied. At
three locations (Coast, Nyeri, and Nakuru County refer-
ral Hospitals), SARI was defined as history of fever or
measured temperature ≥38 °C and cough, with onset
within 14 days that required hospitalization. At the Lwak
and Kibera clinics a modified “SARI” definition was
used, where persons diagnosed with pneumonia [18]
were considered a SARI case regardless of
hospitalization status [19]. Therefore, in addition to pre-
senting analysis based on ILI and SARI status we also
present results by influenza activity periods, and in-
patient vs. outpatient status, knowing that some outpa-
tients may have had been classified as SARI due to
pneumonia diagnosis without hospital admission. The
low influenza periods were defined as <5% of tested ILI
or SARI cases being laboratory confirmed as influenza
during a specific month. Moderate influenza periods
were those where 5–10% of ILI or SARI were laboratory
confirmed; and high influenza periods were those where
>10% of tests resulted in laboratory confirmed cases.
Point of care testing
The BD Veritor™ RIDT is a rapid chromatographic im-
munoassay for the direct and qualitative recognition of
influenza A and B viral nucleoprotein antigens in re-
spiratory specimens (both from nasal and nasopharyn-
geal swabs) and produces results in ten minutes using
an analyzer reader device [20] Fig. 2. The BD Veritor™
System for Rapid Detection of Flu A + B is a rapid chro-
matographic immunoassay for the direct and qualitative
detection of influenza A and B viral nucleoprotein anti-
gens from nasal and nasopharyngeal swabs of symptom-
atic patients. The BD Veritor System for Rapid
Detection of Flu A + B (also referred to as the BD Veri-
tor System and BD Veritor System Flu A + B) is a differ-
entiated test, such that influenza A viral antigens can be
distinguished from influenza B viral antigens from a sin-
gle processed sample using a single device. The respira-
tory specimens are processed using BD RV Reagent D
and then added to the test device. Influenza A or B viral
antigens bind to anti-influenza antibodies conjugated to
detector particles in the A + B test strip. The antigen-
conjugate complex migrates across the test strip to the
reaction area and is captured by the line of antibody on
the membrane. A positive result for influenza A is deter-
mined by the BD Veritor System Reader when antigen-
conjugate is deposited at the Test “A” position and the
Control “C” position on the BD Veritor System Flu A +
B assay device. A positive result for influenza B is deter-
mined by the BD Veritor System Reader when antigen-
conjugate is deposited at the Test “B” position and the
Control “C” position in the BD Veritor System Flu A +
B assay device [20].
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Fig. 1 Map of Kenya showing the geographical location of the participating facilities
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Specimen collection and testing
Surveillance officers collected a nasal (NS) swab, a naso-
pharyngeal (NP) swab and an oropharyngeal (OP) swab
from all patients who met the case definitions for ILI or
SARI. All adult case-patients (aged ≥18 years) who met
the ILI and SARI case definitions were asked to provide
written informed consent. For all case-patients aged <18
years, written informed consent was provided by their
parent/guardian. Children who were aged 7–17 years
were considered mature minors and were asked to pro-
vide their assent in addition to their parent/guardian’s
written informed consent.
One aliquot of a single NS specimen was tested on site
using the BD RIDT, 2) the remaining aliquot from the
same NS specimen was tested by real time reverse tran-
scription polymerase chain reaction (rRT-PCR) at the
KEMRI laboratory after being transported in a propri-
etary BD transport reagent. In addition, the NP and OP
swabs were combined into a single vial of viral transport
media according to Kenya’s routine surveillance standard
operating procedures and tested at KEMRI laboratories
using rRT-PCR.
All NS specimens were processed and tested by RIDT
at each site according to the procedures in the BD RIDT
package insert [20]. BD recommends nasal swabs or
nasopharyngeal swabs specimens for testing with BD
Veritor system Flu A + B test [20]. Briefly, a NS speci-
men was placed in a pre-labeled BD vial containing a
proprietary BD transport reagent. The swab was then
swirled in the media three times and three drops of the
processed sample were then put on a labeled BD RIDT
device and allowed to stand for exactly 10 min and then
inserted into the BD Reader. The reader produces a
positive or negative result for both influenza A and B vi-
ruses separately. After testing the NS samples at the site
using BD RIDT, five drops of the remaining processed
sample were added to BD Veritor system sterile propri-
etary BD transport media and kept at 4 °C in a refriger-
ator, before being shipped to the CDC-supported
KEMRI laboratory in Nairobi, where they were stored at
−70 °C awaiting processing by rRT-PCR.
Combined NP/OP samples collected as part of the
ongoing influenza surveillance system [19] were
placed in cryovials containing 1 mL sterile viral trans-
port media (VTM) and kept at 4 °C in a refrigerator
before being shipped to the KEMRI laboratory in
Nairobi. All samples were transported from the sites
to the laboratory within one week, maintaining cold
chain throughout, where they were all tested for in-
fluenza viral ribonucleic acid (RNA) by rRT-PCR
using specific primers and probes for influenza A and
B viruses as previously described [4, 21].
RNA extraction from the respiratory samples was per-
formed (after aliquots were done) using the viral RNA
mini-kit (Quiagen, Germany) according to the manufac-
turer’s instructions; 140 μl of the respiratory sample in
BD stabilizing reagent was added to a Lysis buffer solu-
tion for the cells to lyse and release the total RNA ma-
terial. One step rRT-PCR was carried out using the
AgPath kit (Applied Biosystems, California, USA).
Fig. 2 Description of BD VeritorTM Rapid influenza diagnostic test kit
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Following the reverse transcription step, a 45 cycle PCR
reaction was run and fluorescence was read at the an-
nealing/extension step. The primers, probes, and positive
controls for all influenza viruses were provided by CDC-
Atlanta. Appropriate negative and positive control speci-
mens were run alongside each reaction. The results were
recorded as cycle threshold (CT) values. When all con-
trols met the stated requirements, any influenza A and B
CT value ≤ 39.9 was recorded as positive. Specimens
with CT values ≥ 40.0 were considered negative, and
those without a CT reading were recorded as negative.
We also documented the cost of purchasing the RIDT
materials and cost for supplies and testing the samples
using rRT-PCR, to calculate the cost of testing a sample
using RIDT compared to rRT-PCR.
Clinical and epidemiologic data collection
Clinical, demographic and epidemiological variables col-
lected and analyzed included: sex and age of patient,
SARI vs. ILI case status, site of testing, prevalence of in-
fluenza viruses during the month of testing, inpatient vs.
outpatient case status, and days from symptom onset to
specimen collection. These data, as well as the BD RIDT
results, were recorded by participating clinicians on
computers, smart phones or paper forms. Data collected
on paper forms were entered into a Microsoft Access
2010 database (Microsoft, Redmond, WA, USA).
Laboratory data were recorded into Freezer works soft-
ware (Data works Development, Inc., 174, Mountlake
Terrace, WA, USA) and merged with epidemiological
information. All data were stored in Microsoft Access or
Structured Query Language (SQL) databases on a cen-
tral server at the CDC office on the KEMRI Campus in
Nairobi.
Statistical analysis
Analysis was performed using SAS software version 9.3
(SAS Institute, Cary, NC). Two evaluations of the BD
RIDT were undertaken: 1) sensitivity, specificity, positive
predictive value (PPV), and negative predictive value
(NPV) of the RIDT were calculated compared to rRT-
PCR performed on the same NS specimen stored in BD
proprietary transport media; and 2) sensitivity, specifi-
city, PPV, and NPV were estimated comparing BD RIDT
results with rRT-PCR results from NP/OP samples
placed in standard VTM, as is routinely undertaken for
influenza surveillance in Kenya. The NS specimen tested
at the KEMRI laboratories (i.e. comparison 1 above) was
considered a “gold standard” for this analysis as this was
the same specimen type that was used for testing by the
RIDT.
All comparisons were performed within the following
strata: sex (male, female), age (persons <5 years and per-
sons aged ≥5 years), days from illness onset to sample
collection (<2 days, ≥2–3, >3–4, >4–5, >5–6, >6–7, >7,
and ≤7 days), days from sample collection to sample
testing (≤7 vs. >7), days from illness onset to sample
testing (≤7 vs. >7), inpatient vs. outpatient, influenza A
vs. B virus, and by influenza prevalence (<5%, 5–10%,
10–15% and >15%). Influenza prevalence was based on
monthly estimates of percentage influenza-positive NP/
OP samples collected from ILI and SARI patients and
tested by rRT-PCR during the study period. The per-
formance parameter results were expressed as 95% con-
fidence intervals (CI) calculated using binomial exact
methods, with P < 0.05 considered significant. Two-
sample Z test was used to test for differences in sample
proportions.
Results
During the study period (July 1, 2013 through July 31,
2014) 3,569 patients were enrolled (median age 2.1 years;
range 2 months – 91 years). Of these, 3,199 patients
provided NS specimens that were tested by BD RIDT
and rRT-PCR; and 3,119 patients provided both NS and
NP/OP specimens for testing by BD RIDT and rRT-PCR
(Fig. 3). Patient characteristics are summarized in
Table 1. The majority (78.5%) of the patients were aged
<5 years. The median age and interquartile range for
those aged <5 years was 1.4 years (0.72, 2.57) and for
those ≥5 years was 10.5 years (6.6, 26.5). Overall, 27.3%
(874 out of 3,199) of the patients presented to Nakuru,
22.6% (722 out of 3,199) to Kibera, 18.6% (595 out of
3,199) to Mombasa, 15.9% (509 out of 3,199) to Nyeri
and 15.7% (501 out of 3,199) to Lwak. Overall, 64.4% of
patients had SARI and 35.6% had ILI. Most (85.2%) pa-
tients had specimens collected ≤7 days after the onset of
symptoms, of which 346 (12.7%) were collected in the
first 48 h. The median time of illness of inpatients was
5.0 days and for outpatients was 3.0 days. Overall, 20%
had specimens collected during low influenza periods
27.4% during moderate influenza periods and 52.6% dur-
ing high influenza periods (Table 1).
Comparison of the BD RIDT to rRT-PCR performance on
NS specimens (N = 3,199)
Of the respiratory specimens collected from 3,199 SARI
and ILI patients tested using the BD RIDT, 462 (14.5%)
were positive. Of these 462 RIDT positive specimens,
404 (87.4%) were positive for influenza A virus only, 56
(12.1%) were positive for influenza B virus only, and 2
(0.4%) were positive for both viruses. Of the 3,119 NS
specimens tested using rRT-PCR, 417 (13.0%) were in-
fluenza virus positive. Of these, 417 influenza positive
samples, 345 (82.7%) were positive for influenza A virus,
70 (16.8%) were positive for influenza B virus, and 2
(0.5%) were positive for both viruses. When compared to
NS specimens placed in BD transport media and tested
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by rRT-PCR, the BD RIDT had an overall sensitivity to
detect influenza A or B viruses of 77.0% (95% Cl, 72.6%–
80.9%), a specificity of 94.9% (95% Cl, 94.0%–95.7%),
PPV of 69.5% (95% Cl, 65.0%–73.6%), and NPV of 96.5%
(95% Cl, 95.7%–97.1%) (Table 2). The PPV was 81.6%
(95% Cl, 72.3%–88.5%) for outpatients and 65.9%
(58.9%–72.7%) for inpatients.
Table 2, shows the performance of BD veritorTM rapid
test compared with real time reverse-transcription poly-
merase chain reaction (RT-PCR) test method for nasal
swabs, by type of influenza, age, influenza prevalence,
time of illness onset to sample collection and site in
Kenya for the study period. The sensitivity and specifi-
city of the BD RIDT did not significantly vary by case
type, age, duration of illness onset to sample collection,
influenza prevalence, virus type, or surveillance site
(Table 2).
Figure 4, shows comparison of influenza positive spec-
imens by month using the BD VeritorTM Rapid influenza
diagnostic test, rRT-PCR performed on nasal specimens,
and rRT-PCR performed on Nasopharyngeal/Oropha-
ryngeal specimens, during the study period. During the
study period, influenza virus detection demonstrated a
marked seasonal variability, ranging from 2.2% to 21.4%
(Fig. 2). The PPV of the BD RIDT was 78.5% (95% CI
73.6–82.6) for the 1,684 specimens collected during pe-
riods when influenza virus prevalence in SARI and ILI
cases was ≥10%, which was significantly higher than the
PPV of 44.7% (95% CI 35.8–53.9) for the 1,515 speci-
mens collected during periods when influenza virus
prevalence was <10% (p < 0.0001). Of the respiratory
specimens from 3,119 SARI and ILI patients tested using
BD RIDT, 452 (14.5%) were positive for an influenza
virus, and of these influenza positive specimens, 394
Fig. 3 Study subjects flow diagram
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(87.2%) were positive for influenza A virus only, 56
(12.4%) were positive for influenza B virus only, and 2
(0.4%) were positive for both viruses. Of the 3119 NP/
OP specimens tested using rRT-PCR, 438 (14.0%) were
influenza virus positive and of these, 343 (78.3%) were
positive for influenza A virus, 92 (21.0%) were positive
for influenza B virus, and 3 (0.7%) were positive for both
influenza A and B viruses.
Table 3, shows the performance of BD veritorTM
rapid test compared with real time reverse-
transcription polymerase chain reaction (RT-PCR) test
method for nasopharyngeal/oropharyngeal swabs, by
type of influenza, age, influenza prevalence, time of
illness onset to sample collection and site in Kenya
for the study period. The BD RIDT on NS specimens
compared to rRT-PCR on NP/OP swabs had an over-
all sensitivity of 67.4% (95% C.I 63.0–71.7%); with a
greater sensitivity to detect influenza A virus 71.7%
(95% C.I 66.8–76.4) when compared to influenza B
virus 43.2% (95% C.I 33.2–54.1%; p < 0.0001). When
detecting influenza A or B virus the overall specificity
was 94.1% (95% C.I 93.2–95.0%); the PPV was 65.3%
(95% C.I 60.9–69.6%); and the NPV was 94.6% (95%
C.I 93.8–95.5%). The sensitivity and specificity of the
BD RIDT did not significantly vary by case type, in-
patient or outpatient status, age, duration of illness
onset to sample collection, influenza prevalence, or
surveillance site (Table 3). However, as in the previ-
ous comparison, the PPV of the BD RIDT was
significantly lower during periods when the prevalence
of influenza viruses was <10% compared to when it
was ≥10% (p < 0.0001). The PPV to detect influenza
viruses was significantly higher in outpatient than in-
patient settings (p < 0.0005) (Table 3).
Discussion
In this study we undertook a large point of care evalu-
ation of the BD Veritor™ RIDT in clinical surveillance
settings at multiple geographic localities in Kenya. When
compared to NS specimens tested by rRT-PCR, the
overall sensitivity of the BD RIDT to detect influenza A
or B viruses was 77%, and specificity was 95%, similar to
the performance of RIDTs in clinical care settings re-
ported in temperate countries [22, 23]. Although RIDTs
can never completely replace the need for viral culture
to characterize influenza viruses, they may have a role to
play in sub-Saharan Africa as they have the potential to
reduce laboratory transport and diagnostic costs in rou-
tine influenza surveillance. RIDTs also have potential to
inform clinicians and public health departments about
when influenza viruses are circulating and relative levels
of influenza activity.
The per-specimen rRT-PCR cost, including reagent
purchases and RNA extractions at the KEMRI laboratory
in Kenya (not including specimen collection and trans-
port) is ~ $13.3 USD. This can conservatively be com-
pared to a per-test cost of $10.6 USD of the BD-Veritor
system. In the context of many competing priorities and
Table 1 Demographic characteristic of the study participants in Kenya, July2013–July 2014 (n = 3,199)
Variable Kibera n = 722 Lwak n = 499 Mombasa n = 595 Nakuru n = 874 Nyeri n = 509 Total
Case Type % % % % % n %
Department
Outpatients 722 100.0 499 100.0 146 24.5 308 35.2 44 8.6 1719 53.7
inpatients 0 0.0 0 0.0 449 75.5 566 64.8 465 91.4 1480 46.3
Case Type
ILI 350 48.5 292 58.5 146 24.5 308 35.2 44 8.6 1140 35.6
SARI 372 51.5 207 41.5 449 75.5 566 64.8 465 91.4 2059 64.4
Gender
Female 373 51.7 251 50.3 240 40.3 407 46.6 208 40.9 1479 46.2
Male 349 48.3 248 49.7 355 59.7 467 53.4 301 59.1 1720 53.8
Age
< 5 years 392 54.3 317 63.5 569 95.6 767 87.8 467 91.7 2512 78.5
≥ 5 years 330 45.7 182 36.5 26 4.4 107 12.2 42 8.3 687 21.5
Flu Activity
Low < 5 121 16.8 90 18.0 109 18.3 130 14.9 190 37.3 640 20.0
Medium(≥5–10) 254 35.2 153 30.7 212 35.6 145 16.6 111 21.8 875 27.4
High(>10) 347 48.1 256 51.3 274 46.1 599 68.5 208 40.9 1684 52.6
ILI influenza like illness
SARI Severe acute respiratory illness
In-Patients patients who had SARI and were exclusively admitted in the wards
* if RNP negative it implies poor specimen
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Table 2 Performance of BD rapid test compared with rRT-PCR test for nasal swabs in Kenya, July 2013–July 2014 (N = 3,199)
Characteristic Specimens %Sensitivity %Specificity %PPV %NPV
n, %positive (CI, 95%) (CI, 95%) (CI, 95%) (CI, 95%)
Influenza Type
Influenza A or B 321 10.0 77.0 (72.6–80.9) 94.9 (94.0–95.7) 69.5 (65.0–73.6) 96.5 (95.7–97.1)
Influenza A 270 8.4 77.8 (73.0–82.0) 95.8 (94.4–96.0) 66.5 (61.7–71.0) 97.2 (96.5–97.8)
Influenza B 46 1.4 63.9 (51.7–74.6) 99.6 (99.3–99.8) 79.3 (66.3–88.4) 99.2 (98.9–99.4)
Case Type:
SARI (n = 2059) 178 8.6 74.2 (68.1–79.5) 94.9 (93.7–95.8) 65.7 (59.7–71.3) 96.5 (95.6–97.3)
ILI (n = 1140) 143 12.5 80.8 (73.4–82.4) 95.0 (94.4–96.0) 74.9 (61.5–70.9) 96.4 (96.7–97.9)
Department:
Inpatienta (n = 1480) 122 8.2 76.3 (69.3–82.8) 95.2 (93.9–96.3) 65.9 (58.9–72.7) 97.1 (96.0–97.9)
Outpatient (n = 498) 80 16.1 87.0 (77.9–92.8) 95.6 (93.0–97.3) 81.6 (72.3–88.5) 97.0 (94.7–98.4)
Age:
< 5 years (n = 2512) 237 9.4 78.0 (72.8–82.4) 95.1 (94.1–96.0) 68.7 (63.5–73.5) 96.9 (96.1–97.6)
≥ 5 years (n = 687) 84 12.2 74.3 (65.1–81.9) 94.3 (91.9–96.0) 71.8 (62.6–79.5) 94.9 (92.7–96.5)
Illness onset to sample collection:
Less than 2 days (n = 346) 23 6.6 65.7 (47.7–80.3) 92.0 (88.2–94.6) 47.9 (33.5–62.6) 96.0 (92.9–97.8)
≥ 2 to 3 days (n = 1267) 145 11.4 79.2 (75.5–84.7) 95.5 (94.0–96.6) 74.7 (67.9–80.6) 96.5 (95.1–97.4)
> 3 to 4 days (n = 454) 44 9.7 80.0 (66.7–89.1) 94.5 (91.6–96.4) 66.7 (53.9–77.5) 97.2 (94.8–98.5)
> 4 to 5 days (n = 337) 30 8.9 75.0 (58.5–86.8) 96.0 (92.9–97.8) 71.4 (55.2–83.8) 96.6 (93.7–98.3)
> 5 to 6 days (n = 237) 21 8.9 77.8 (57.3–90.6) 95.2 (91.2–97.6) 67.7 (48.5–82.7) 97.1 (93.5–98.8)
> 6 to 7 days (n = 174) 18 10.3 69.2 (48.1–84.9) 93.9 (88.4–97.0) 66.7 (46.0–82.8) 94.6 (89.2–97.4)
> 7 days (n = 298) 23 7.7 76.7 (57.3–89.4) 95.9 (92.6–97.8) 67.6 (49.4–82.0) 97.3 (94.4–98.8)
≤ 7 days (n = 2727) 280 10.3 77.6 (72.8–81.7) 94.9 (93.9–95.7) 69.8 (65.0–74.2) 96.5 (95.7–97.2)
Sample collection to sample testingb:
> 7 days (n = 2834) 305 10.8 76.3 (71.9–80.4) 95.2 (94.3–96.0) 72.4 (67.9–76.6) 96.1 (95.2–96.8)
≤ 7 days (n = 365) 16 4.4 94.1 (69.2–99.7) 92.8 (89.4–95.2) 39.0 (24.6–55.5) 99.7 (98.0–100)
Influenza Prevalence
Influenza activity <5% (n = 640) 13 2.0 72.2 (46.4–89.3) 95.7 (93.7–97.1) 32.5 (19.1–49.2) 99.2 (98.0–99.7)
Influenza activity 5to10% (n = 875) 42 4.8 76.4 (62.7–86.3) 95.0 (93.2–96.3) 50.6 (39.5–61.7) 98.4 (97.2–99.1)
Influenza activity >10to15% (n = 354) 28 7.9 71.8 (54.9–84.5) 95.2 (92.1–97.2) 65.1 (49.0–78.5) 96.5 (93.6–98.1)
Influenza activity >15% (n = 1334) 238 17.9 78.1 (73.0–82.5) 94.4 (92.7–95.7) 80.5 (75.4–84.7) 93.5 (91.8–94.9)
Influenza activity ≥10%(n = 1684) 266 15.8 77.3 (72.5–81.6) 94.6 (93.2–95.7) 78.5 (73.6–82.6) 94.2 (92.8–95.4)
Flu activity <10% (n = 1515) 56 3.6 75.3 (63.6–84.4) 95.3 (94.0–96.3) 44.7 (35.8–53.9) 98.7 (97.9–99.2)
Surveillance Site:
Kibera (n = 722) 85 11.8 73.9 (64.7–81.5) 95.6 (93.5–99.7) 75.9 (66.7–83.3) 95.1 (93.1–96.6)
Lwak (n = 499) 34 6.8 68.0 (53.2–80.1) 92.7 (89.7–94.8) 50.7 (38.4–63.0) 96.3 (94.0–97.8)
Mombasa (595) 55 9.2 79.7 (68.0–88.1) 95.1 (92.7–96.7) 67.9 (56.5–77.6) 97.3 (95.4–98.4)
Nakuru(874) 110 12.6 84.6 (77.0–90.1) 94.0 (91.9–95.5) 71.0 (63.0–77.8) 97.2 (95.7–98.3)
Nyeri (n = 509) 37 7.3 69.8 (55.5–81.3) 97.8 (95.9–98.9) 78.7 (63.9–88.8) 96.5 (94.3–97.9)
ILI influenza like illness, SARI Severe acute respiratory illness
aIn-Patients patients who had SARI and were exclusively admitted in the wards
bTime to sample tested refer to the rRT-PCR only since all RIDT was performed at bedside
PPV positive predictive value
NPV negative predictive value
CI Confidence interval
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funding challenges, the sustainability of influenza senti-
nel surveillance is a serious consideration in many African
countries [21, 24, 25]. As a result, innovative methods to
reduce the cost of surveillance and to generate timely
feedback of test results to clinicians have to be considered,
perhaps with a known subset of specimens (e.g. those of
greater severity, those in severe illness clusters, or those
with epidemiologic-linkages to high risk exposures etc.)
sent for rRT-PCR and viral culture analyses.
The moderately high sensitivity observed in this study
may relate to the fact that 80% of the ILI and SARI case-
patients tested were aged <5 years, and RIDTs have been
shown to have relative high sensitivity among young
children because of increased influenza viral load com-
pared to older children and adults [26, 27]. The sensitiv-
ity of RIDTs can be substantially diminished among
adults (~18%), [28] and some studies have shown even
lower sensitivity among those ≥65 years (8%) [29–31],
leading to underestimation of disease burden [32, 33].
There were no significant differences in the sensitivity
and specificity of the BD RIDT compared to rRT-PCR by
age, surveillance site, and duration from illness onset to
sample collection. However, as expected, PPV was sub-
stantially lower during low influenza periods [13, 34].
The PPV was ~30% for specimens tested by the RIDT
during low influenza activity (<5% influenza-positive
samples), and ~50% when the prevalence of positive
samples for influenza was between 5–10%.
While RIDTs have some promise for surveillance pur-
poses, the relatively unpredictable and variable seasonality
of influenza in Kenya also presents some challenges to the
practical utility of RIDTs [4, 35] for clinical decision-
making. In the U.S., empiric antiviral treatment is recom-
mended as soon as possible for patients with confirmed or
suspected influenza who are at increased risk for compli-
cations from influenza, without waiting for the results of
influenza testing. This is possible because negative test
results (especially RIDTs) do not exclude a diagnosis of in-
fluenza during influenza season [36]. This problem would
only be exacerbated in the Kenyan context where there is
continuous but variable annual circulation. In low resource
settings there may be a desire to base use of antiviral ther-
apy on positive RIDT results; however, the high frequency
of false positive results during periods when influenza
prevalence is <10% would result in inappropriate use of
antiviral treatment for many RIDT positive patients.
Our study had several limitations. Even though our in-
tent was to evaluate the performance of the RIDT in pa-
tients of all ages, our study population was primarily
children <5 years, with median age of 1.4 years, and
therefore our findings cannot be generalized to all
adults. Also, these results reflect a single year of influ-
enza virus circulation in Kenya and could vary in other
years when influenza activity has different patterns and
levels. Although almost half of the cases presented
within 72 h of illness onset, most samples (88.6%) were
tested >7 days from the time they were collected, and
this could have reduced the sensitivities of both the
RIDT and rRT-PCR to detect influenza viruses. The pro-
longed time in the freezer, before testing, could have af-
fected the sensitivity of the rRT-PCR, hence the lower
rate of positivity by rRT-PCR when tested >7 days com-
pared to RIDT. However, Caselton, et al. [37], there was
no statistically significant difference in influenza positiv-
ity of specimens stored up to five days when compared
to zero to one day, but they described a reduction in
positivity rates after this period. Finally, nasopharyngeal
washes typically yield higher viral titers than nasopha-
ryngeal swabs [38], and the BD Veritor TM test was only
indicated for use in nasal and nasopharyngeal swabs [20]
and not oral pharyngeal swabs at the time of our study.
Given the improved influenza viral yield from the use of
NP/OP relative to NS swabs, future validation of the
RIDT assay using NP/OP specimens could be warranted.
Fig. 4 Comparison of influenza positive specimens by month using RIDT and rRT-PCR
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Table 3 Performance of BD rapid test compared with rRT-PCR test for NP/OP swabs in Kenya, July 2013–June 2014 (N = 3,119)
Characteristic Specimens %Sensitivity %Specificity %PPV %NPV
n %positive (CI, 95%) (CI, 95%) (CI, 95%) (CI, 95%)
Influenza Type
Influenza A or B 295 9.5 67.4 (63.0–71.7) 94.1 (93.2–95.0) 65.3 (60.9–69.6) 94.6 (93.8–95.5)
Influenza A 248 8.0 71.7 (66.9–76.4) 94.7 (93.8–95.5) 62.6 (57.9–67.4) 96.4 (95.7–97.1)
Influenza B 41 1.3 43.2 (33.2–54.1) 99.4 (99.2–99.7) 70.7 (58.0–82.4) 98.2 (97.8–98.7)
Case Type:
SARI (n = 1995) 160 8.0 65.0 (58.7–70.9) 94.1 (92.9–95.1) 60.8 (54.6–66.7)) 95.0 (93.9–96.0)
ILI (n = 1124) 135 12.0 70.3 (63.2–75.6) 94.2 (92.5–95.6) 71.4 (63.3–77.6) 93.9 (92.1–95.3)
Department:
Inpatienta (n = 1,429) 105 7.3 69.5 (61.4–76.6) 94.1 (92.6–95.3) 58.0 (50.4–65.2) 96.3 (95.1–97.3)
Outpatient (n = 489) 77 15.7 80.2 (70.5–87.4) 94.7 (91.8–96.6) 78.6 (68.9–86.0) 95.1 (92.4–97.0)
Age:
< 5 years (n = 2,443) 217 8.9 70.5 (65.0–75.4) 94.2 (93.1–95.1) 63.7 (58.4–68.9) 95.7 (94.9–96.6)
≥ 5 years (n = 676) 78 11.5 60.0 (51.0–68.4) 93.8 (90.5–94.9) 69.6 (57.3–74.9) 90.8 (88.1–93.1)
Duration of illness onset to sample collection:
Less than 2 days (n = 341) 23 6.7 54.8 (38.8–69.8) 92.0 (88.1–94.7) 48.9 (34.3–69.7) 93.5 (90.0–96.0)
≥ 2 to 3 days (n = 1245) 133 10.7 68.2 (61.1–74.6) 94.5 (92.9–96.7) 69.6 (62.5–76.0) 94.1 (92.5–95.4)
> 3 to 4 days (n = 443) 44 9.9 69.8 (56.8–80.4) 94.2 (91.2–96.3) 66.7 (53.9–77.5) 95.0 (92.1–96.9)
> 4 to 5 days (n = 326) 25 7.7 73.5 (55.3–86.5) 94.5 (91.1–96.7) 61.0 (44.5–75.4) 96.8 (93.9–98.5)
> 5 to 6 days (n = 232) 21 9.1 75.0 (54.8–88.6) 95.1 (90.9–97.5) 67.7 (48.5–82.7) 96.5 (92.7–98.5)
> 6 to 7 days (n = 170) 16 9.4 59.3 (39.0–77.0) 93.0 (86.7–96.0) 61.5 (40.7–79.1) 92.4 (86.7–96.0)
> 7 days (n = 453) 34 7.5 61.8 (47.7–74.3) 93.7 (90.6–95.8) 56.6 (44.1–70.2) 94.7 (91.8–96.6)
≤ 7 days (n = 2666) 261 9.8 68.1 (63.2–72.7) 94.2 (93.2–95.1) 66.4 (61.5–71.0) 94.6 (93.6–95.5)
Time of sample collection to sample testing:
> 7 days (n = 2,773) 281 10.1 67.7 (62.9–72.1) 94.4 (93.3–95.2) 67.9 (63.1–72.3) 94.3 (93.3–95.2)
< 7 days (n = 346) 14 4.0 60.9 (38.8–79.5) 92.6 (89.0–95.1) 36.8 (22.3–54.0) 97.1 (94.4–98.6)
Influenza Prevalence
Flu activity <5% (n = 619) 11 1.8 91.7 (59.8–99.6) 95.6 (93.5–97.0) 28.9 (16.0–46.1) 99.8 (98.9–100)
Flu activity ≥ 5to < 10%(n = 857) 33 3.9 53.2 (40.2–65.8) 94.1 (92.3–95.6) 41.3 (30.5–52.8) 96.3 (94.6–97.4)
Flu activity >10–15% (n = 342) 28 8.2 70.0 (53.3–82.9) 95.0 (91.8–97.1) 65.1 (49.0–78.5) 96.0 (92.9–97.8)
Flu activity >15% (n = 1301) 223 17.1 68.8 (63.4–73.8) 93.0 (91.2–94.5) 76.6 (71.3–81.3) 90.0 (87.9–91.7)
Flu activity ≥10% (n = 1,643) 251 15.3 69.0 (63.9–75.6) 93.5 (92.0–94.8) 75.1 (70.1–79.6) 91.4 (89.7–92.8)
Flu activity <10% (1,476) 44 3.0 59.5 (47.4–70.5) 94.7 (93.4–95.8) 37.3 (28.7–46.7) 97.8 (96.9–98.5)
Site:
Kibera (n = 707) 79 11.2 60.3 (51.4–68.6) 95.3 (93.2–96.8) 74.5 (65.0–82.3) 91.3 (88.7–93.4)
Lwak (494) 34 6.9 56.7 (43.3–69.2) 92.4 (89.5–94.7) 50.7 (38.4–63.0) 93.9 (91.1–95.9)
Mombasa(n = 562) 45 7.9 72.6 (59.6–82.8) 93.3 (90.6–95.2) 57.0 (45.4–67.9) 96.5 (94.4–97.9)
Nakuru (n = 851) 102 12.0 77.9 (69.6–84.4) 92.9 (90.7–94.6) 66.7 (58.5–73.9) 95.8 (94.0–97.2)
Nyeri (n = 500) 35 7.0 64.1 (50.6–77.8) 97.3 (95.2–98.5) 74.5 (59.4–84.9) 95.8 (93.4–97.4)
an for inpatient/outpatient =1944; ILI influenza like illness, SARI severe acute respiratory illness
In-Patients patients who had SARI and were exclusively admitted in the wards
PPV positive predictive value
NPV negative predictive value
CI confidence interval
rRT-PCR real time reverse-transcription polymerase chain reaction
NP/OP nasopharyngeal/Oropharyngea
Ndegwa et al. BMC Infectious Diseases  (2017) 17:60 Page 10 of 12
Indeed, when compared to rRT-PCR undertaken on NP/
OP swabs, the use of the RIDT on NS specimens re-
sulted in our missing ~30% of true influenza cases. This
was due in part to the reduced performance of the RIDT
against rRT-PCR, and in part to the use of NS vs NP/OP
swabs.
Conclusion
In conclusion, the BD VeritorTM System RIDT demon-
strated a moderately high sensitivity and high specificity
in NS specimens when used predominately in young
children at pediatric clinical sites in Kenya. While they
are not sufficient on their own for clinical decision-
making related to influenza in these contexts, RIDTs
may have a role in promoting sustainable and timely in-
fluenza surveillance, particularly in remote locations
where transportation of specimens to laboratories for
rRT-PCR testing is difficult.
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